Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes
about
Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisFusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.The future of antisense therapy: combination with anticancer treatments.Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo.Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progressionRole of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination.Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence.Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition.c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells.A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination.BCR/ABL regulation of PI-3 kinase activity.Interplay between the retinoblastoma related pRb2/p130 and E2F-4 and -5 in relation to JCV-TAg.
P2860
Q30168802-802921FF-9529-43FA-A6EA-3CFD3A4EEC5EQ30175784-00ED6712-2A87-4D57-BA27-3ABAC8280CDDQ34281241-9324C5B0-72A9-4A3A-AA4A-702824F1F55CQ34325748-0F328837-4174-4334-973F-53F9E7FA29A5Q35551139-E6A94585-B1A1-41B4-936C-BEA4FE601394Q36108131-8EE02E73-F28D-4CFD-9636-72FEAD214E32Q39615527-AD2EEBBC-7BD9-41BF-9A25-39CD7BA08126Q39940494-939B75EF-4B9B-4A0D-B5BA-815A8BC2C489Q40443957-B8FFACC0-CA6D-4FAC-897B-850646E4FFCDQ40709933-1C97A872-9474-4A5F-A67D-EC4F65BD8658Q41141202-C276EDE2-8D78-42DD-B9B3-4CFC38F2D59DQ42115767-03B40A05-4F0B-4BDD-8078-5CC8393C1429Q44133878-04315614-D10B-4CFF-BE48-2090F1FEEA50Q44393125-717D139C-10EB-451C-9093-CC6DDFC7CCDEQ46547433-13167535-F614-4A91-AF9C-B97935EC2885Q53449790-CC73093B-DA32-49B0-94E5-6D70884DAE4CQ53563438-4A52F09C-D1B7-4DD0-B374-6F3AC2962CB2
P2860
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@ast
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@en
type
label
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@ast
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@en
prefLabel
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@ast
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@en
P2093
P2860
P356
P1476
Leukemia treatment in severe c ...... argeting cooperating oncogenes
@en
P2093
B Calabretta
K Campbell
M Nieborowska-Skorska
P2860
P304
P356
10.1084/JEM.182.6.1645
P407
P577
1995-12-01T00:00:00Z